Tough Stuff

SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.

Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.

Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.

Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.

Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.

Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.

Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.